

Formulary Adherence Checklist for NICE Technology Appraisals About Medicines



Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

Milton Keynes Health Economy

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. **Version 20 September 2018**

All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE			
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)
2018/2019						
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)	03/09/2018	Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin	x		26/09/2018	23 NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)	29/08/2018	Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults	x		26/09/2018	28 NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Dinutuximab beta for treating neuroblastoma (TA538)	22/08/2018	Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least partially responded to induction chemotherapy, followed by myeloablative therapy and stem cell transplant	x		26/09/2018	35 NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Ixezumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)	08/08/2018	Ixezumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults	x		26/09/2018	49 CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)	08/08/2018	Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults	x		26/09/2018	49 NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)	08/08/2018	Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine	x		26/09/2018	49 NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements

Dupilumab for treating moderate to severe atopic dermatitis (TA534)	01/08/2018	Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults	x		26/09/2018	56	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)	25/07/2018	Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features	x		26/09/2018	63	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Cenegermin for treating neurotrophic keratitis (TA532)	18/07/2018	Cenegermin is not recommended, within its marketing authorisation, for treating moderate or severe neurotrophic keratitis in adults	x		26/09/2018	70	Not recommended
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)	18/07/2018	Pembrolizumab is recommended as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations.	x		26/09/2018	70	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)	04/07/2018	Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy.	x		25/07/2018	21	Not recommended
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)	04/07/2018	Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults	x		25/07/2018	21	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)	04/07/2018	Niraparib is recommended for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based	x		25/07/2018	21	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)	27/06/2018	Interferon beta-1a is recommended as an option for treating multiple sclerosis	x		25/07/2018	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)	13/06/2018	Arsenic trioxide is recommended, within its marketing authorisation, as an option for inducing remission and consolidation in acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)	13/06/2018	Atezolizumab is recommended as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)	13/06/2018	Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Midostaurin for untreated acute myeloid leukaemia (TA523)	13/06/2018	Midostaurin is recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed acute FLT3-mutation-positive myeloid leukaemia with	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)	13/06/2018	Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable	x		25/07/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Guselkumab for treating moderate to severe plaque psoriasis (TA521)	13/06/2018	Guselkumab is recommended as an option for treating plaque psoriasis in adults	x		25/07/2018	42	CCG commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)	16/04/2018	Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour),	x		23/05/2018	37	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA519)	25/04/2018	Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy	x		23/05/2018	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Tocilizumab for treating giant cell arteritis (TA518)	18/04/2018	Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults	x		23/05/2018	35	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
Avelumab for treating metastatic Merkel cell carcinoma (TA517)	11/04/2018	Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease.	x		23/05/2018	42	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and the National Cancer Drugs Fund requirements
			% "Yes"	% "N/A"	-		Average implement time (days)
Adherence statistics for 2018-19			100%	0%			41